The present application provides a use of a nitric oxide-releasing agent in preparing a drug for preventing or treating an epithelial tissue disease related to EGFR inhibition in a subject. The present application also provides a pharmaceutical composition and kit comprising an EGFR inhibitor and the nitric oxide-releasing agent.